Claims for Patent: 7,659,285
✉ Email this page to a colleague
Summary for Patent: 7,659,285
| Title: | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| Abstract: | Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. |
| Inventor(s): | Weiner; David M. (San Diego, CA), Davis; Robert E. (San Diego, CA), Brann; Mark R. (Rye, NH), Andersson; Carl-Magnus A. (Hjarup, SE), Uldam; Allan K. (Ballerup, DK) |
| Assignee: | Acadia Pharmaceuticals, Inc. (San Diego, CA) |
| Application Number: | 11/416,855 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,659,285 |
| Patent Claims: |
1. A method of treating Parkinson's Disease psychosis in a patient, comprising administrating to a patient having Parkinson's Disease a therapeutically effective amount of
N-(1-methylpiperidin-4-yl)-N-(4-flourophenylmethyl)-N'-(4-(2-methylpropyl- oxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof.
2. A method of treating Parkinson's Disease psychosis in a patient, composing administrating to a patient having Parkinson's Disease a pharmaceutical composition comprising from about 10 mg to about 50 mg of N-(1-methylpiperidin-4-yl)-N-(4-flourophenylmethyl)-N-'-(4-(2-methylpropy- loxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof. 3. Then method of claim 1, wherein about 10 mg of N-(1-methylpiperidin-4-yl)-N-(4-flourophenylmethyl)-N'-(4(2-methylpropylo- xy)phenylmethyl)carbamide of a pharmaceutically acceptable salt thereof is administered. 4. The method of claim 1, wherein about 25 mg of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyl- oxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof is administered. 5. The method of claim 1, wherein about 50 mg of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyl- oxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof is administered. 6. The method of claim 1 or 2, wherein the composition is administered once daily. 7. The method of claim 1, wherein about 0.01 mg/kg of body weight to about 1.5 mg/kg body weight of the compound is administered. 8. The method of claim 1, wherein the tartrate salt of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyl- oxy)phenylmethyl)carbamide is administered. 9. The method of claim 2, wherein the tartrate salt of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyl- oxy)phenylmethyl)carbamide is administered. 10. The method of claim 1, wherein the hydrochloride salt of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyl- oxy)phenylmethyl)carbamide is administered. 11. The method of claim 2, wherein the hydrochloride salt of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyl- oxy)phenylmethyl)carbamide is administered. |
